Take the Fight

Information for Pharmacists about the ALVESCO Instant Rebate Card

In these tough economic times, ALVESCO is helping asthma patients control their disease by reducing their copay to $0 with the ALVESCO Instant Rebate Card.

How it Works

  • For qualifying patients, the insurance copay will be reduced to $0 if it is currently $75 or less. If the copay is more than $75 or the patient is paying cash, they will receive $75 in savings.
  • Discount available on up to twelve (12) prescriptions/refills for ALVESCO.

Help Your Asthma Patients Save Money

Let your asthma patients know about the $0 copay program when they present a new or refill prescription for an inhaled corticosteroid (ICS). If they are interested in ALVESCO:

  • 1.  Offer to contact their healthcare provider to determine if ALVESCO is an appropriate alternative.
  • 2.  Enroll the patient in the program by calling 866-782-7852, then press 2.

If the patient is qualified for the program, the claim will be available for processing within 30 minutes. Follow the instructions below.

Processing an Electronic Pharmacy Claim is Easy

Simply follows these steps for electronic processing:

1. Input primary insurance information first, if available.

2. Enter the ALVESCO card information:

  • Rx Group Number
  • RX Bin Number 610524
  • Patient's ID number

The card information should be entered:

  • As secondary insurance for patients with primary insurance
  • As primary insurance for patients paying cash

3. Submit the pharmacy electronic prescription transaction.

Applicable discounts on the copay amount will be applied and the cost to be collected from the patient will be displayed.

If your pharmacy does not accept loyalty cards, the patient can still get the benefit by requesting a refund for the copay. Simply instruct the patient to:

  • 1. Save the receipt from the ALVESCO prescription payment, and
  • 2. Contact the number on the card to request reimbursement

Note the card must be activated prior to use either online at www.alvesco.us or by calling 866-782-7852.

Program Support

For questions regarding setup, claims transmission, patient eligibility, or other issues, call the ALVESCO Instant Rebate Program at 866-782-7852, then press 2. Live pharmacy assistance is available from 8:00 AM – 8:00 PM EST, Monday thru Friday.

ALVESCO Instant Rebate Program Eligibility

Please be aware of the following program requirements:

  • Valid only for qualified customers with a valid prescription for ALVESCO Inhalation Aerosol. No substitutions permitted.
  • Not valid for prescriptions covered or paid for by Medicare (including true out-of-pocket expenses under Medicare Part D), Medicaid, or any other federal or state healthcare programs, such as state pharmaceutical assistance programs.
  • Not valid for patients who are Medicare eligible and enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees (e.g. you are eligible for Medicare Part D but receive a prescription drug benefit through a former employer).
  • A parent or guardian must enroll in the ALVESCO Instant Rebate Program on behalf of a patient under 18 years of age.

 

Submission of claims for the ALVESCO Instant Rebate program are subject to the LoyaltyScript® program Terms and Conditions established by McKesson Specialty Arizona Inc. By accepting and using this card from the patient, you agree: (i) to abide by the LoyaltyScript® program Terms and Conditions posted at www.mckessonspecialty.com and (ii) that your  participation in this program is consistent with all applicable state laws and any obligations, contractual or otherwise, which you are subject to as a pharmacy provider.

 

For asthma control, start with ALVESCO

Deliver powerful results with...

Potent anti-inflammatory effect directly to the lungs

Convenient dosing available in 2 strengths (80 mcg per actuation and 160 mcg per actuation)

- Dose indicator (counter)

Only ALVESCO...

Knocks Down
Copays to $0 for EVERY Rx!

with the ALVESCO Instant Rebate Program†

* Maximum benefit is $75 off, on up to 12 prescriptions/refills of ALVESCO per year. Not valid for patients participating in Medicare, Medicaid, government (public insurance) programs, and where prohibited by law. Click here for program rules.

Do your patients have nasal allergies too?

To learn about a different product to treat nasal allergy symptoms plus a great money-saving offer, visit www.ReliefIsHere.com.


INDICATION: ALVESCO is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION

ALVESCO is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.

Rare cases of hypersensitivity reactions with manifestations such as angioedema, with swelling of the lips, tongue, and pharynx, have been reported.

The development of localized infections of the mouth and pharynx with Candida albicans have occurred infrequently. In clinical trials, the development of localized infections of the mouth and pharynx with Candida albicans occurred in 32 of 3038 patients treated with ALVESCO. Most cases of candida infection were mild to moderate.

ALVESCO is NOT indicated for the relief of acute bronchospasm.

Patients who are on immunosuppressant doses of corticosteroids are more susceptible to infections and should avoid exposure to chickenpox and measles and seek prompt medical attention if exposed. Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

Particular care is needed for patients who are transferred from systemically active corticosteroids due to the potential for adrenal insufficiency. Patients should taper slowly from systemic corticosteroids if switching to ALVESCO.

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear in a small number of patients particularly when ALVESCO is administered at higher than recommended doses over prolonged periods of time. If such effects occur, the dosage of ALVESCO should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids and management of asthma.

Decreases in bone mineral density have been observed with long-term administration of products containing inhaled corticosteroids. Patients with major risk factors for decreased bone mineral content should be monitored and treated with established standards of care.

Orally inhaled corticosteroids may cause reduction in growth velocity when administered to pediatric patients. Monitor the growth of pediatric patients receiving ALVESCO. To minimize the systemic effects, patients should be titrated to the lowest dosage that effectively controls symptoms.

Glaucoma, increased intraocular pressure, and cataracts have been reported following the administration of inhaled corticosteroids including ALVESCO. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.

If bronchospasm occurs following dosing with ALVESCO, it should be treated immediately with a fast-acting inhaled bronchodilator.

The most common adverse reactions occurring at an incidence greater than or equal to 3% in any of the ALVESCO groups and which were more frequent with ALVESCO compared with placebo were headache, nasopharyngitis, sinusitis, pharyngolaryngeal pain, upper respiratory infection, arthralgia, nasal congestion, pain in extremity, and back pain.

Full Prescribing Information for ALVESCO.

Prescribing InformationPatient Instructions for UseSitemapPrivacy StatementTerms & ConditionsMedical DisclaimerUnsubscribe

and SEPRACOR are registered trademarks of Sepracor Inc. ALVESCO is a registered trademark of Nycomed GmbH, used with permission.